<strike id="brxe7"></strike>
          <wbr id="brxe7"></wbr>
            1. <form id="brxe7"></form>

                <nav id="brxe7"></nav>

                Redefining care for type 2 diabetes

                Type 2 diabetes develops as a result of prolonged insulin resistance and insufficient insulin production. It is, in many cases, linked to obesity and lifestyle factors such as inactivity. The rising prevalence of obesity is driving the type 2 diabetes pandemic, and diabetes is now among the top 10 causes of death globally1. Type 2 diabetes is associated with long-term damage to vital organs, including the kidneys and heart, and effective glucose lowering has been shown to reduce the risk of serious complications2,3. To enable more effective interventions and better long-term outcomes, Novo Nordisk scientists are currently refining the treatment of type 2 diabetes – for example, by advancing from subcutaneous injections to oral administration. Our research focus has also expanded from only reducing blood glucose levels, to also treating related complications.

                ?

                Do you want to know more about living with type 2 diabetes?
                Learn more on Diabetes What's Next


                Type 2 diabetes

                Type 2 diabetes accounts for around 90% of all cases of diabetes4

                Type 2 diabetes

                People with obesity are 5 x more likely to develop type 2 diabetes5
                ?

                Type 2 diabetes

                People with type 2 diabetes are
                2–4 x more likely to develop cardiovascular disease6


                Engineering to overcome nature's barriers


                Glucagon-like-peptide-1 (GLP-1) is a hormone that induces insulin secretion, and has numerous beneficial effects on vital organs, including the pancreas, heart, and liver7. For this reason, GLP-1 analogues are increasingly used as treatment for people with type 2 diabetes.

                Native GLP-1, however, is rapidly broken down by enzymes like DPP-4 in the blood stream.?At Novo Nordisk, we have a long history and strong expertise in overcoming such barriers by using protein engineering to transform natural proteins like GLP-1 into medicines.

                ?

                Explore our expertise in prolonging the action of proteins like GLP-1.


                Meet the scientist

                Oral GLP-1s: a new frontier for treatment delivery

                Proteins like insulin and GLP-1 are destroyed by human digestive enzymes in the gastrointestinal tract if they are ingested orally. Consequently, today's insulin and GLP-1 treatments must be delivered by injection. Scientist Jian Wu works at Novo Nordisk R&D in Denmark as part of a team that is pursuing a true breakthrough for patients – an oral GLP-1 treatment for type 2 diabetes.

                If you are interested in joining one of our research and development teams, explore your opportunities at our careers page.

                LinkedIn profile

                View R&D jobs


                Type 2 diabetes

                Novo Nordisk and Emisphere

                To support our commitment to developing effective and convenient treatments for the benefit of people with serious chronic conditions, Novo Nordisk has partnered with Emisphere Technologies to pursue a common goal of developing orally administered protein-based treatments.

                ?

                Explore partnering possibilities

                Getting to the heart of type 2 diabetes

                t2d 70pct

                In people with diabetes, 70% of deaths are attributable to cardiovascular disease6? ??


                Cardiovascular disease (CVD) is the #1 cause of morbidity and mortality in people with diabetes globally. In Novo Nordisk, we take patients’ increased risk of cardiovascular disease highly serious. We focus our research on new therapeutics which not only reduce blood glucose levels but also reduce the risk of cardiovascular events. To learn more about the link between type 2 diabetes and CVD, and how to protect the type 2 diabetic heart, visit our Heart of Type 2 page for more information.


                facilities oxford

                A new global base for innovation

                In September 2018, our scientists in Oxford, UK, moved into new facilities at the University of Oxford. This location underpins the close collaboration between Novo Nordisk scientists and scientists at the university, who have forged an alliance to discover new therapies for people living with type 2 diabetes.

                ?

                Visit our global R&D facilities


                DISEASE EXPERIENCE EXPERT PANELS

                Guided by the people who know best

                At Novo Nordisk, we consider people living with serious chronic diseases to be experts. That's why we invite them to become members of our Disease Experience Expert Panels (DEEPs). DEEP members are able to provide disease-specific insights and advice based on real-world experiences. This input guides us as we work to develop better treatments and meaningful support for people living with chronic diseases worldwide.

                Explore DEEP

                ?

                Deep

                Follow our progress

                Explore our scientists’ work on new treatments for type 2 diabetes.

                ?


                Recent publications

                publications thumbnail

                To contribute to the scientific community in our areas of expertise, we take pride in publishing our scientists’ new findings. Visit our library to review some of their recent work.

                ?

                Explore our publications

                ?

                ?

                A network that changes lives

                Clinical trials thumbnail

                Novo Nordisk conducts clinical trials in over 50 countries worldwide, and we have a high retention rate among our trial participants.


                ?

                Our clinical trials

                ?

                ?

                References

                赌城手机赌博